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years after the first human liver transplantation was performed in Denver, 
the procedure has finally gained acceptance as the preferred treatment for 
most forms of end-stage liver disease. 1 
Essential elements of an organ transplant program include organ pro-
curement and preservation, organ implantation, immunosuppression and 
the management of allograft rejection, and the management of complica-
tions, including infection. In this review, advances in each of these areas 
as they apply to the recent progress in liver transplantation will be dis-
cussed. 
Organ Procurement and Preservation 
Organ Donation 
The concept of brain death is now well established and accepted 
throughout the United States and Western Europe, but this was not easily 
accomplished and still remains a barrier to the development of organ trans-
plantation in many other countries. In the United States, the public has 
also strongly supported a voluntary system of organ donation. 
Organ donation has increased significantly in the past several years as a 
result of the extensive educational efforts of professional organizations and 
the media attention the field has received. Legislation at both state and 
federal levels has further encouraged organ donation and facilitated organ 
sharing and distribution. Nevertheless, organ preservation technology is 
still crude and storage times are limited, especially for livers and hearts. 
Frequent organ sharing across large distances is often difficult or impracti-
cal. Even if all the available donors in the country were utilized and organ 
sharing became a frequent and widespread practice, the need for organs 
would still exceed the available supply. 
Some of the greatest resistance to organ donation has originated within 
the medical profession. Physicians of dying patients are often reluctant to 
explore the possibility of organ donation at what is always a sensitive and 
difficult time for both physician and family. Today much support is avail-
able to physicians, nurses, and donor families from the highly professional 
organ procurement agencies throughout the United States. Educational 
programs sponsored by local and regional procurement agencies, the 
North American Transplant Coordinators Organization (NATCO), and var-
ious medical societies and foundations have contributed greatly to public 
and professional awareness. "Required request" legislation mandating re-
quests by hospitals for organ donation in appropriate circumstances has 
now been passed in many states. This legislation often includes mecha-
nisms for state assistance for the development of organ donation programs 
by community hospitals. 
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Advances in Organ Procurement Surgery 
Application of methods for the rapid core cooling of solid organs by 
aortic infusion of cold electrolyte- or colloid-containing solutions has re-
sulted in effective and reliable methods for the retrieval of the liver and/or 
pancreas, kidneys, and heart or heart-lungs from a single brain-dead, 
heart-beating cadaver donor. Comprehensive descriptions of the methods 
for multiple organ retrieval developed at the University of Pittsburgh have 
been published and the reader is referred to these articles for technical 
details.2, 3 Recently a significant modification in methodology has been de-
veloped that greatly shortens the time required to complete the organec-
tomies, with no loss of graft quality. 4 
In the original description of the method for multiple organ retrieval, the 
most time-consuming and dangerous part of the procedure involved me-
ticulous dissection of the hepatic hilum, including identification and pres-
ervation of the often anomalous arterial supply to the liver. Cold core cool-
ing was not performed until this preliminary dissection, which often 
required 2 or more hours, was completed. Manipulation of the liver during 
this long period of dissection could interfere intermittently with either portal 
or hepatic artery blood flow, producing warm ischemic injury to the liver. 
Furthermore, many donors were unstable and could not tolerate such a 
long operative procedure. 
In an effort to salvage unstable donors, the original procedure was mod-
ified by early cannulation and flushing of the distal aorta. Rapid core cool-
ing of the abdominal organs was then possible, permitting prompt retrieval 
of the liver or pancreas and kidneys in a bloodless field. 
This rapid method of organ retrieval has now become our standard 
method of organectomy. As soon as the thoracic procurement team 
surgeon is ready to arrest the heart, or if the donor spontaneously ar-
rests, the upper abdominal aorta is crossclamped and cold core perfu-
sion is immediately begun through cannulas in the inferior mesenteric vein 
and distal aorta. Once the heart is removed and the liver completely 
flushed, a rapid, bloodless dissection of the hepatic hilum is performed, 
with care taken to identify and preserve any anomalous vessels. In this 
manner, the donor hepatectomy can be completed by an experienced sur-
geon in approximately 30-45 minutes. The kidneys-undisturbed, com-
pletely flushed clear of blood, and cold-can then be rapidly removed en 
bloc. 
The quality of the livers procured by this rapid technique has been su-
perior to that of organs obtained by the conventional method. Peak trans-
aminase levels within 48 hours of revascularization of the liver, which were 
often greater than 1,000 IU using the original methods, are now often less 
than 500 IU. The incidence of delayed renal graft function requiring di-
alysis within 1 week after transplantation has been lower than with other 
methods of kidney retrieval. 
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Donor Assessment and Selection 
It has been customary to evaluate the suitability of a potential liver do-
nor based on traditional indicators of ischemic injury, including liver func-
tion tests, coagulation profile, oxygenation, blood pressure, level of pressor 
support, number and duration of cardiac arrests, and cause of death. How-
ever, these parameters of donor assessment can easily be applied too rig-
orously and may be much less reliable in predicting graft quality than has 
been assumed. In a retrospective analysis of 219 consecutive organ do-
nors, we evaluated the reliability of liver function tests, arterial blood gas 
values, blood pressure, and cause of death in predicting early graft out-
come and found that these parameters were difficult to rely on in predict-
ing poor outcome.5 If conservative criteria were applied for the evaluation 
of donor organs, a high degree of organ wastage would result. Further-
more, over half the donors rated as poor in fact gave livers with excellent 
early function. Since the need for organs far exceeds the available supply, 
restrictive criteria for donor acceptance that result in high levels of organ 
wastage are very damaging. 
We continue to study this problem to develop a reliable model for the 
prediction of early graft outcome. In the meantime, we have liberalized our 
criteria for donor acceptance, without a discernible penalty. 
Advances in Recipient Surgical Technique 
Venovenous Bypass 
A dangerous period during the operation in the recipient is the an hepatic 
phase when the native liver has been removed and the inferior vena cava 
and portal vein are occluded. During this period there is massive seque-
stration of blood volume in the peripheral venous circulation of the lower 
body and in the mesenteric venous circulation. The gastrointestinal tract 
becomes diffusely edematous, high renal vein pressure may result in de-
terioration of renal function, and bleeding from high pressure in the thin-
walled venous collaterals found throughout the abdomen in patients with 
portal hypertension often increases. Volume preloading is required to 
maintain cardiac performance but can easily result in hypervolemia and 
pulmonary edema after revascularization of the liver. The high potassium 
and acid load returned to the systemic circulation after unclamping also 
poses a Significant risk to the patient. 
To reduce these risks and maintain physiologic stability during the an-
hepatic phase of surgery, a venovenous bypass technique is now routinely 
employed in most adults and selectively in children.6-8 The inferior vena 
cava (through the saphenofemoral system) and portal vein are cannulated 
and blood is returned to the heart through a cannula in the axillary vein 
'. 
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(Fig 1). The patient is not given systemic heparin but the bypass tubing is 
heparin bonded and the system is primed with 350 ml of saline containing 
dilute heparin (2,000 lUll). Using the bypass it is possible to maintain 
hemodynamic parameters at prehepatectomy levels without volume pre-
loading. The intestinal tract remains uncongested except for a brief period 
during reconstruction of the portal vein. Renal venous hypertension is 
avoided, and as a result the incidence of renal failure requiring postoper-
ative dialysis is less than 5%. Blood loss is reduced since use of the bypass 
provides time to oversew the large bare areas created by the hepatectomy 
and prevents the development of high pressure in venous collaterals. 
Early placement of venous bypass facilitates completion of the recipient 
hepatectomy, especially dissection of the vena cava. With the portal vein 
mobilized and the surgeon free to lift the liver without compromising ve-
suprahepatic 
bare area 
common bile rl",..,--1::I 
inTrahepatic 
portal 
ex.t. tliac vein 
FIG 1. 
9mm qott tubing 20" 
mm ~ott tuhinJ 20" 
Venovenous bypass during the an hepatic phase of liver transplantation. Outflow 
cannulas are placed in the iliofemoral system via the saphenous vein and in the 
portal vein. Return to the heart is obtained through a cannula placed in the axillary 
vein. The axillary vein is repaired after withdrawl of the bypass. (From Griffith BP, 
et al: Veno-venous bypass without systemic anticoagulation for transplantation of 
the human liver. Surg Gynecol Obstet 1985; 160:270. Reproduced by permission.) 
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nous return, dissection of the infrahepatic and suprahepatic vena cava is 
simplified. Use of the bypass has enabled us to offer transplantation to 
higher risk patients such as older patients9 and patients with poorly devel-
oped collateral channels who might not tolerate venous occlusion. 
Technique of Vascular Anastomosis 
Hepatic artery thrombosis is the second most common major technical 
complication after liver transplantation and has occurred in our experience 
in approximately 7% of cases. 10 The highest incidence (25%) has been in 
children under 1 year of age. The mortality associated with this complica-
tion is over 50%, and most patients require retransplantation. 
Hepatic artery thrombosis manifests in one of three general patterns: 
frank hepatic gangrene, delayed biliary leak, or relapsing bacteremia. 11 
The principal injury is ischemia of the bile duct system with bile duct or 
ductule necrosis and intrahepatic or extrahepatic bile extravasation. It must 
be suspected in all patients who suddenly become febrile after transplan-
tation, who develop a biliary fistula, bile peritonitis or a bile abscess, or 
who have a blood culture positive for gram-negative organisms. Liver 
function tests may reflect massive hepatic necrosis or may show only mild 
or moderate changes similar to those seen with rejection. Doppler ultra-
sound is a useful screening modality, but arteriography is indicated for 
definitive diagnosis if hepatic artery pulsations are not clearly detected on 
the Doppler study. 
Portal vein and vena cava stenosis or thrombosis are rare complica-
tions. 12 Sudden symptoms of portal hypertension such as variceal bleed-
ing, coagulopathy, encephalopathy, and oligUria suggest portal vein throm-
bosis, and a venous phase arteriogram is indicated. 
Our preferred method of vascular anastomosis for the vena cava, portal 
vein, and hepatic artery is end-to-end anastomosis with continuous non-
absorbable monofilament polypropylene suture. A potential hazard of this 
technique is suture line "purse-string" stenosis at the anastomosis resulting 
from continuous tension exerted on the suture during performance of the 
anastomosis. Furthermore, the hepatic artery is frequently in severe spasm 
during anastomosis and may not fully dilate until many hours after the 
completion of the surgery. 
To prevent suture line stenosis, an "expansion factor" is provided (Fig 
2).13 The running suture is tied several millimeters or more from the wall 
of the blood vessel such that when the vessel distends under pressure or 
when vasospasm resolves, the suture can soak into the vessel and defor-
mity at the anastomosis is prevented. A stay suture tied flush to the vessel 
immediately adjacent to the "expansion factor" prevents separation and 
leakage of the anastomosis at this critical point. We believe that use of this 
technique has greatly reduced the incidence of hepatic artery stenosis and 
thrombosis. 
Arterial revascularization in small children is demanding. Our preferred 
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FIG 2. 
Suture technique for venous and arterial anastomosis in liver transplantation. 1, 
• intraluminal performance of posterior wall anastomosis for vena caval or portal vein 
anastomosis after placement and tying of sutures. For arterial anastomosis, conven-
tional extraluminal technique is used and the vessel is then rotated 1800 to coIl}-
plete the opposite wall. 2, the mate of one end suture is used to construct the 
other half of the circumference. 3, the two ends are tied together away from the 
vessel wall. 4, expansion and bulging of the suture line are evident as the extra 
polypropylene suture is taken up. (From Starzl TE, et al: A growth factor in fine 
vascular anastomoses. Surg Gynecol Obstet 1984; 159:164-165. Reproduced by 
permission. ) 
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method is to anastomose the donor celiac artery to the proximal common 
hepatic artery at the level of the origin of the recipient splenic artery. The 
recipient splenic artery is ligated so that all flow is into the graft. The con-
fluence of the recipient splenic and celiac arteries provides a larger orifice 
for anastomosis to the donor. 
If direct revascularization is not possible, a free-standing graft of donor 
iliac artery is sewn to the recipient infrarenal aorta, passed through a tunnel 
posterior to the pancreas and duodenum, and then anastomosed to the 
donor celiac artery. Donor aortic conduits left in continuity with the donor 
hepatic arterial supply have largely been abandoned because of a high 
incidence of thrombosis. 
Technique of Biliary Tract Reconstruction 
Biliary tract leaks or obstructions are the most frequent technical com-
plications after liver transplantation. lO Fortunately, most of these, if recog-
nized and dealt with promptly, can be successfully managed. Standardiza-
tion of our methods for biliary tract reconstruction has Significantly reduced 
the incidence of biliary tract complications. 
Duct to duct reconstruction over an external T-tube stent is our pre-
ferred method of reconstruction in patients without preexisting extrahepatic 
biliary tract disease and when there is no significant size discrepancy be-
tween the donor and recipient bile ducts. Advantages of this method in-
clude preservation of the sphincter of Oddi and availability of the T tube 
to monitor bile production, and for cholangiography. The T tube provides 
an important mold for the healing bile duct, and the upper limb of the T 
tube should reach to the hepatic duct bifurcation. The T tube is usually left 
in place for 6-8 weeks. 
In many patients, preexisting disease of the extrahepatic biliary system 
or unfavorable anatomy precludes direct duct to duct repair. In these 
cases, anastomosis of the donor bile duct to the side of the distal portion 
of an 18-inch Roux-en-Y limb of proximal jejunum is used. The duct anas-
tomosis is performed over a small polyethylene pediatric feeding tube cath-
eter which eventually passes out spontaneously through the gastrointes-
tinal tract. Roux-en-Y choledochojejunostomy is the safest method of 
biliary reconstruction, with a complication rate of less than 8%. Failures of 
duct to duct repair are usually best managed by conversion to this method 
of reconstruction. 
Immunosuppression and the Management of Rejection 
Cyclosporine 
Between March 1, 1963, and February 1980, 170 patients received or-
thotopic liver transplants and conventional immunosuppression with aza-
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thioprine and high-dose prednisone. Twenty-eight (16.5%) of these pa-
tients remain alive, including 15 patients now more than 10 years after 
transplantation. From March 1980 through August 1986, 720 patients re-
ceived liver transplants and cyclosporine and low-dose prednisone for im-
munosuppression, and through October 1986, 494 (68.6%) were alive. 
The patient survival curves for our accumulated experience with azathio-
prine and cyclosporine therapy are presented in Figure 3. These results 
emphasize that the principal benefit of cyclosporine therapy has been bet-
ter control of acute rejection during the first 6 months after transplantation. 
Acute rejection has been less frequent and easier to treat in patients man-
aged with cyclosporine than in patients managed with conventional ther-
apy. In addition, late survival has been better in cyclosporine-treated pa-
tients, and this may be a benefit of the lower maintenance doses of 
steroids which can be used with cyclosporine, resulting in a reduced risk 
of life-threatening infectious complications. 
Survival in Adults Treated With Cyclosporine 
The five most common indications for transplantation in adults are cir-
rhosis (168 cases), primary biliary cirrhosis (122 cases), sclerosing cholan-
gitis (58 cases), primary liver tumors (35 cases), and inborn errors of me-
tabolism (25 cases). Survival rates after transplantation for these 
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FIG 3. 
Actuarial survival rates for 170 liver recipients treated between 1963 and 1980 with 
conventional azathioprine-prednisone immunosuppression and 720 liver recipients 
treated since 1980 with cyclosporine-prednisone therapy. 
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A. actuarial survival rates for adult liver recipients who underwent transplantation 
for cirrhosis (mostly chronic aggressive hepatitis), primary biliary cirrhosis, scleros-
ing cholangitis, primary liver tumors, and inborn errors of metabolism. B. actuarial 
survival rates for pediatric liver recipients who underwent transplantation for biliary 
atresia, inborn errors of metabolism, cirrhosis, familial cholestasis, and neonatal 
(giant cell) hepatitis. 
indications in adults are shown in Figure 4,A and all are similar except for 
survival after transplantation for primary liver malignancy and for patients 
with surface antigen-positive hepatitis. 
Our experience with transplantation for primary liver malignancy has 
been disappointing. 14 Early survival after transplantation for cancer has 
been excellent, but long-term survival has been poor because of a very 
high incidence of recurrent disease, usually within 1 year of transplanta-
tion. There are some notable exceptions. Patients with the fibrolamellar 
variant of hepatocellular carcinoma have also had a high recurrence rate 
but palliation has often been achieved for more than 1 year. Patients with 
epitheloid hemangioepithelioma of the liver have usually enjoyed long-
term survival. 
There are 14 patients in our experience who were discovered to have 
incidental hepatic cancers confined to the liver at the time of transplanta-
tion for other diseases such as postnecrotic cirrhosis. All 14 patients have 
survived without recurrence of cancer. This observation suggests that most 
'. 
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patients with hepatic tumors too extensive for conventional resection have 
disease that is not curable by transplantation, but that survival after trans-
plantation in patients with early malignant disease truly confined to the 
liver is possible. 
Patients positive for hepatitis B surface antigen (HBsAg) are at high risk 
of recurrence of hepatitis after transplantation. Hyperimmune globulin has 
not been effective in preventing recurrence. A trial of interferon therapy is 
presently under way. 
Survival in Children Treated With Cyciosporine 
Survival rates for patients 18 years of age or less at the time of liver 
transplantation is presented in Figure 4,B. Biliary atresia accounted for ap-
proximately half of the cases, and survival was excellent except for infants 
(less than 1 year old), in whom a high incidence of technical complications, 
especially hepatic artery thrombosis, limited early survival to only 60% and 
necessitated retransplantation in approximately 25% of the patients. Post-
necrotic cirrhosis, inborn errors of metabolism, familial cholestasis, and 
neonatal (giant cell) hepatitis accounted for most of the other pediatric 
cases, and survival has been good for all of these indications. 
Complications of Cyclosporine Therapy 
Hypertension is a common side effect of cyclosporine therapy and most 
patients require additional drugs to control it. In the acute postoperative 
recovery period, intravenous control with intermittent doses of apresoline 
or labetalol or continuous infusion of nitroglycerin or labetalol may be re-
quired. Later, oral therapy with hydralazine and a l3-adrenergic blocker is 
often effective. Recently we have had favorable experience with calcium 
channel-blocking drugs (nifedipine, Vasotec) or labetalol. 
Many bacterial infections are better tolerated with cyclosporine than with 
azathioprine. In part this may be due to the selective mechanism of action 
of cyclosporine on T lymphocytes and in part to the lower doses of pred-
nisone required to prevent rejection. However, opportunistic infections 
such as Pneumocystis and Legionnella pneumoniae and systemic viral in-
fections, especially with herpes simplex or zoster, varicella, Epstein-Barr 
virus, and cytomegalovirus, are a serious threat. We currently treat all our 
liver recipients with oral Bactrim (trimethoprim-sulfamethoxazole) prophy-
laxis (one single strength tablet each day) for Pneumocystis for 6 months 
after transplantation. 
Localized herpetic lesions in the oral and genital areas are common and 
can be treated by topical or oral acyclovir therapy. Disseminated infection 
is treated with reduction of immunosuppression and the intravenous ad-
ministration of acyclovir. Although there are experimental antiviral agents 
for treatment of other viral infections, for the most part these can only be 
managed by reduction or withdrawal of immunosuppressive agents. 
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Epstein-Barr virus infection in patients taking cyclosporine is associated 
with the development of lymphomatous lesions. Involvement of mesen-
teric and retroperitoneal lymph nodes may produce abdominal pain and 
intestinal obstruction or perforation. Lesions in the head and neck region 
are also common and may result in oropharyngeal or airway obstruction. 
The lesions will usually regress with withdrawal of cyclosporine. Radiation 
therapy or chemotherapy is rarely indicated. 15 . 
Cyclosporine is a nephrotoxic drug, and elevated blood urea nitrogen 
(BUN) and serum creatinine levels are common in patients taking this im-
munosuppressive agent in therapeutic doses. Fortunately, irreversible renal 
injury severe enough to require dialysis has been uncommon. However, 
patients with a difficult early postoperative course may require sparing of 
cyclosporine to preserve renal function. Alternative therapy with conven-
tional immunosuppression or antilymphocyte globulin can be used for this 
purpose. 
Antilymphocyte Therapy 
OKT3 (Orthoclone), Ortho Pharmaceuticals, Raritan, N. J.) is a mouse 
antihuman monoclonal T lymphocyte antibody preparation. It is an effec-
tive agent for the control of steroid-resistant acute cellular allograft rejec-
tion. Its mechanism of action is probably complex and may include both 
physical removal of antibody-coated cells by the reticuloendothelial system 
and functional inactivation of the T cell antigen receptor. 
In over 2 years' experience with this agent we have found it to be par-
ticularly helpful in the management of acute cellular rejection during the 
period from 10 to 90 days after transplantation. It is also valuable in the 
first week after transplantation for patients unable to tolerate therapeutic 
doses of cyclosporine. 16 
OKT3 is administered as a single daily intravenous 5-mg bolus (1.0-2.5 
mg in small children). Side effects including malaise, nausea, myalgias ar-
thralgias, and headaches are common but rarely severe enough to require 
withdrawal of therapy, and usually diminish with succeeding doses. Pre-
medication with steroids and antihistamine is used for the first several days. 
No deaths immediately attributable to administration of OKT3 have oc-
curred in our experience. 
Retransplantation 
In our first 500 liver transplants done with cyclosporine, 22.7% of the 
patients required retransplantation. Allograft rejection necessitated 53.1 % 
of the retransplants. Fortunately, survival after retransplantation for allo-
graft rejection is nearly 60%, almost as good as survival after primary 
transplantation. 
Technical failure, mainly hepatic artery thrombosis, was responsible for 
27.9% of the retransplants. More retransplants were required for hepatic 
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artery thrombosis in children (39.8%) than in adults (16.2%). One-year 
survival after retransplantation for loss of a primary graft from technical 
complications is only 43.1 %. 
Primary graft failure results in an immediate life-threatening crisis. These 
patients rapidly develop coagulopathy, oliguria, and severe acid-base and 
electrolyte abnormalities, and frequently become septic. Urgent retrans-
plantation is the only hope, and survival even then only has been 27.4%. 
As discussed earlier, prediction of poor early graft function based on donor 
assessment by traditional parameters is not very reliable except in extreme 
cases. 
Long-Tena Morbidity and Mortallty 
The rehabilitation of patients after successful liver transplantation is ex-
cellent, and most enjoy a quality of life comparable to that enjoyed before 
the onset of liver disease. The risk of death beyond the first year after 
transplantation is less than 3 %.17 The most frequent cause of death be-
yond a year after transplantation is graft failure from rejection. It is impor-
tant to continue to monitor graft function and maintain adequate immu-
nosuppression indefinitely. 
The second most common cause of late death after liver transplantation 
is recurrent liver malignancy. The vast majority of patients who underwent 
transplantation because of liver tumors that could not be treated by con-
ventional resection have died within 2 years of transplantation with recur-
rent disease. 12 De novo malignancies after liver transplantation have been 
rare, and five of the six lesions seen in our series have been cyclosporine-
dependent lymphomatous lesions associated with Epstein-Barr virus infec-
tions. As discussed previously, these lesions will usually regress with reduc-
tion or withdrawal of immunosuppression. 15 
Most technical complications occur within the first few months after 
transplantation, but bile duct strictures may present at any time. Liver func-
tion abnormalities often resemble those seen in rejection. Ultrasound and 
even liver biopsy are often unreliable since low-grade rejection may remain 
undetected. Direct visualization of the biliary tree by endoscopic or trans-
hepatic cholangiography is required for accurate diagnosis. The etiology of 
late strictures is not known but it may in some cases result from injury 
caused by episodes of graft rejection. 
Chronic nephrotoxicity from cyclosporine is common but only two pa-
tients have had to be switched to alternative therapy. Chronic dialysis has 
not been required in any of our patients maintained on cyclosporine for 
2-5 years after transplantation. We recommend conversion to conven-
tional therapy with azathioprine and prednisone only in extraordinary cir-
cumstances when cyclosporine cannot be tolerated. We have, however, 
used combination therapy with moderate-dose azathioprine (50-100 mg! 
day) and reduced cyclosporine for patients unable to tolerate therapeutic 
levels of cyclosporine. 
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Multiple Organ Transplants 
In 1984 a 6-year-old girl with end-stage heart disease from homozygous 
familial hypercholesterolemia became the first successful recipient of a si-
multaneous heart and liver transplant. 18, 19 The liver transplant was per-
formed to correct the genetic defect in hepatic metabolism responsible for 
her heart disease. Follow-up studies have demonstrated successful correc-
tion of the metabolic defect. 20 The child has returned to school and is 
growing well. Two subsequent combined heart-liver transplants were at-
tempted but failed for technical reasons. 
Combined liver and kidney failure has led us to perform simultaneous 
liver and kidney transplants in 10 patients. In most of these cases, com-
bined transplantation was done for severe renal failure occurring as a com-
plication of end-stage liver disease. In one case polycystic disease of both 
liver and kidneys and in another case polycystic kidneys and congenital 
hepatic fibrosis necessitated a double transplant. All were patients in whom 
recovery of renal function was thought unlikely or whose function was so 
impaired that they would be unable to tolerate cyclosporine immuno-
suppression. 
In all cases except one, the liver and kidney were obtained from the 
same donor, and in all cases but one the kidney was transplanted imme-
diately after completion of the liver transplant. Eight of the latter kidneys 
were transplanted within 24 hours of harvest and functioned promptly. 
The only exception was in a patient with a positive crossmatch whose liver 
functioned. In general, kidneys transplanted in combination with a liver 
have functioned well, and patients have tolerated the higher doses of cy-
closporine required for liver transplantation. Eight of the ten liver-kidney 
recipients are surviving and in seven, both grafts are functioning. 
Conclusion 
Survival after liver transplantation has improved dramatically for both 
adults and children since the introduction of cyclosporine. Technical im-
provements, including use of a venovenous bypass and standardized 
methods of biliary tract reconstruction, have also contributed to reduced 
morbidity and mortality. 
Liver transplantation is the treatment of choice for most patients with 
end-stage liver disease and offers better long-term survival and quality of 
life for patients with cirrhosis complicated by esophageal varices, intracta-
ble ascites, or encephalopathy than does sclerotherapy or peritoneal-ve-
nous or portosystemic shunting, 
Portoenterostomy for biliary atresia must be reassessed in view of the 
advantages of successful liver transplantation and the potential difficulties 
created by futile repeated surgical forays into the hepatic hilum. Survival 
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of infants after liver transplantation is not as good as in older children, and 
there is a perpetual severe shortage of donors for small children. A suc-
cessful portoenterostomy provides a grace period, allOwing for additional 
growth and development and later transplantation. However, attempts at 
revision of failed operations and creation of stomas makes liver transplan-
tation more difficult if not impossible. 
Liver replacement for primary hepatic malignancy has been disappoint-
ing for most types of cancer. Additional methods of treatment must be 
developed to improve the prognosis for these patients. 
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